Fujifilm has become the latest in a long line of biopharmas to see a failure for its Alzheimer’s drug.
The efficacy seen in the trials suggests the combinations can treat most cystic fibrosis patients, opening the door to a multibillion-dollar market.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
Check out the rest of Tuesday's news of note.
As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies.
The third late-phase success sets Paratek up to file for approval, although incidence of vomiting and nausea cast a shadow over the data.
Check out today's best of the rest of biopharma news.
CymaBay has taken a look at its ongoing midstage test for its liver med seladelpar, and is happy with what it sees.
Officials are making the cash available to implement recommendations the U.K. sees establishing it as the first port of call for drug development.
Allena Pharma has been granted orphan status by the FDA for a drug to treat primary hyperoxaluria.
GlaxoSmithKline has confirmed that Pfizer’s SVP of medicinal sciences has jumped ship to work for the British Big Pharma.